Point of Care/Rapid Diagnostics Market

Point of Care/Rapid Diagnostics Market by Product (Glucose, Infectious Disease (Hepatitis C, Influenza), Coagulation), Platform (Microfluidics, Immunoassay), Mode of Purchase (Prescription, OTC), Enduser (Hospital, e-comm, Home Care) - Global Forecast to 2025

Report Code: MD 2702 Feb, 2021, by marketsandmarkets.com

[240 Pages Report] The global point of care diagnostics market size is projected to reach USD 50.6 billion by 2025 from USD 29.5 billion in 2020, at a CAGR of 11.4% during the forecast period. The global point of care diagnostics market offers significant growth potential for prominent as well as emerging product manufacturers. Technological advancements in POC devices, rising incidence of infectious dieases, and increase in the investments by key players are key factors driving the growth of the point of care diagnostics market.

Point of Care/Rapid Diagnostics Market

To know about the assumptions considered for the study, Request for Free Sample Report

COVID-19 Impact on the global point of care diagnostics market

The COVID-19 pandemic has significantly affected the point of care diagnostics market. The outbreak of COVID-19 has expedited the global demand for diagnostic kits to rapidly detect thedisease. However, countries across the globe are facing a severe shortage of laboratory-based molecular assays. Thus, many players are emphazing on increasing the supply of tests worldwide.

The point-of-care diagnostics market will witness significant growth in 2020, owing to the increasing usage of POC tests that can rapidly diagnose COVID-19. With the increase in the demand for speedy diagnostic results, the adoption of point of-care testing is booming. The rapidly growing number of COVID-19 cases and the growing pressure on governments to improve patient management has boosted the demand for rapid antigen testing kits that can be effectively used in point-of-care settings.Such rapidly detecting tool are vital in providing accurate treatment option.

Moreover, the increasing prevalence of other respiratory illnesses across the globe, the shift towards decentralized diagnostics, and improved access to point-of-care devices through online platforms are some of the other key factors likely to drive the long-term growth of the point-of-care diagnostics market in the mear future.

Clinical Microbiology  Market Dynamic

Driver: Increase in the prevalence of Infectious dieases

POC tests can greatly improve the management of infectious diseases, especially in developing countries where access to timely medical care is a challenge, and the healthcare infrastructure is sparse. In addition, government funds and grants for developing novel products are also fueling the adoption of advanced technologies for infectious diseases diagnosis. Such initiatives have made it easier for people in underdeveloped and developing countries to afford these tests. Factors such as the rising number of clinics adopting POC testing for the rapid detection of infectious diseases in the near future are expected to drive market growth during the forecast period

Restraint: Strigent Regulatory policies

Despite the high demand for POC devices, manufacturers face several regulatory barriers due to multi-layered regulations set by the FDA and laboratory regulations under CLIA which is required for the for the premarket approval of POC testing kits. For the approval of any new POC device in the US, manufacturers must submit performance data to the FDA. This should demonstrate that healthcare professionals and patients can use these devices and obtain results similar to clinical laboratory tests. POC tests intended for point-of-laboratory (POL) testing also require special recognition from the FDA with additional onsite performance data. Such implantation of stringent regulations can become a major factor hindering the market growth.

Opportunity: Healthcare Decentralization

The US healthcare system is already decentralized, and several European countries are also focusing ondecentralizing their respective healthcare systems. Furthermore, many countries have begun to decentralize HIV treatment to primary healthcare centers to decrease the burden of HIV services Decentralization aims to increase the efficiency of treatment and citizen participation as well as improve access to healthcare services at a regional level thus increasing the accessibility of point of care devices for the early diagnosis of diseases.

Challenge: Inadeqaute adoption of POC in professional settngs

A majority of POC tests are performed by clinical personnel, such as medical assistants and nurses, who have limited laboratory knowledge. These individuals focus on patient care and are always under pressure to deliver fast treatments, as hospitals have a large number of patients. Clinical personnel performing POC tests are often unfamiliar with routine laboratory procedures like sample collection, calibration, and proper patient preparation. Additionally, In most cases, it has been observed that the view of healthcare and lab professionals from hospitalis not taken into consideration during the use of POCT devices in hospitals; also, they are unaware of a number of current POCT devices available in the market.

By product, glucose monitoring segment is expected to have the largest market share during the forecast period

The large share of this segment is attributed to factors such as the significant adoption of new technologies among researchers and academia technological advancements, growing diabetic patient population base, and the growing preference for home glucose testing.

lateral flow assays is the largest platform segment of the point of care diagnostics market

The segment captured a largest market share owing to the adavanatge offerd by lateral fow assay assays in POC testing by replacing lengthy, conventional laboratory procedures. Rise in the awareness of such adavantages and the strong focus of many players towards the developemnt of innovative LFA-based POC devices are likely to boost the of the lateral flow assay in the near future.

OCT testing products accounted for the largest share of the point of care diagnostics market, by end users, in 2020

The growing prevalence of chronic and infetious diseases and the demand for the early detection of diseases and the growing awareness about the avaolibility of OCT poc products for the home use are likely to fuel the growth of Oct testing product segment during the forecast period.

Hospitals & critical care centers accounted for the largest share of the point of care diagnostics market, by end users, in 2020

The segment accounted for the highest share owing to the increasing prevalence of chronic diseases in need of long-term care and frequent monitoring in the critical care units and rapidly growing awareness of the presence of cost-effective and highly innovative POC diagnostic products. Moreover, the rise in the number of hopitals and critical care centers, reduction in the patient waiting time with the use of rapid POC tets, and the initiatives undertaken by government to provide improved care top the patient in hopitals are likely to propel the growth of this segmnt.

Point of Care/Rapid Diagnostics Market  by Region

To know about the assumptions considered for the study, download the pdf brochure

North America is the largest regional market for Point of care diagnostics

North America (comprising the US and Canada) dominates point of care diagnostics market. North America is a gaining traction with the increasing incidence and prevalence of lifestyle diseases. Moreoer resence of major key platers in the region, facourable government scenarios, higher awarness of self tetsing and home care products and significant adoption of novel technologies are likely to paly a major role in fueling the growth of the point of care diagnostics market in the North America.

Key Market Players

Roche Diagnostics (Switzerland), Siemens Healthineers (Germany), Danaher Corporation (US), Becton Dickinson and Company (US), Abbott Laboratories (US), Quidel Diagnostics (US), and Chembio Diagnostics (US). Other prominent players operating in this market are EKF Diagnostics (UK), Trinity Biotech (Ireland), and Fluxergy (US).

Roche Diagnostics was founded in 1896 and is headquartered in Basel, Switzerland. The company specializes in offering medicines for oncology, virology, inflammation, metabolism, and other areas. The company operates through two business divisions—pharmaceuticals and diagnostics. The diagnostics division operates through four segments: centralized point-of-care solutions, diabetes care, molecular diagnostics, and tissue diagnostics. The company has adopted several strategies, such as product launches, product approvals, and acquisitions, and focused on implementing data management to existing pharmaceutical & diagnostic businesses to sustain its global position in the market. The company operates 23 manufacturing facilities and 29 research facilities worldwide. Roche Diagnostics has a strong geographical presence across North America, Europe, Latin America, Africa, and Asia.

Scope of the Report

Report Metric

Details

Market Size Available for Years

2017–2025

Base Year Considered

2019

Forecast Period

2020–2025

Forecast Units

Value (USD Billion)

Segments Covered

Product, Platform, Mode of Purchase, End Users and Region

Geographies Covered

North America (US & Canada), Europe (Germany, the UK, France, Italy, Spain, and RoE), APAC (Japan, China, Australia, South Korea India, and the RoAPAC), LATAM (Brazil, Mexico, and RoLATAM), and MEA

Companies Covered

Roche Diagnostics (Switzerland), Abbott Laboratories (US), Siemens Healthineers (Germany), Becton, Dickinson and Company(US), Johnson & Johnson (US), Danaher Corporation (US), Chembio Diagnostics (US), Quidel Corporation(US), EKF Diagnostics (UK), Trinity Biotech (Ireland), AccuBioTech (China), Nova Biomedical (US), PTS Diagnostics (US), Instrumentation Laboratory Company (US), and Sekisui Diagnostics (US).

This research report categorizes the point of care diagnostics market based on product, platform, mode of purchase, end users and region.

By Product

  • Glucose Monitoring Products
  • Cardiometabolic Monitoring Products
  • Infectious Disease Testing Products
  • Coagulation Monitoring Products
  • Pregnancy & Fertility Testing Products
  • Fecal Occult Testing Products
  • Hematology Testing Products
  • Tumor/Cancer Marker Testing Products
  • Urinalysis Testing Products
  • Drugs-of-abuse Testing Products
  • Cholesterol Testing Products
  • Other POC Products

By Platform

  • Lateral Flow Assays
  • Immunoassays
  • Microfluidics 1
  • Molecular Diagnostics
  • Dipsticks

By Mode of Purchase

  • OTC Testing Products
  • Prescription-based Testing Products

By End Users

  • Outpatient & Ambulatory Care Facilities
  • Hospitals & Critical Care Centers
  • Home Care Settings 5
  • Other End Users

By Region

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • RoE
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • RoAPAC
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East and Africa

Recent Developments

  • In 2019, Roche Diagnostics FDA approval for the VENTANA PD-L1 (SP142) Assay for identifying triple-negative breast cancer (TNBC) patients.
  • In 2019, Abott anouced the launch of Afinion HbA1c Dx Assay , a point of care test for diabetes.
  • In 2019, Quidel Corporation received US FDA approval to commercialize Quidel Triage TOX Drug Screen
  • In 2019, Danaher acquired the Biopharma business of GE Life Sciences with an aim to established as a standalone operating company and strengthen the point of care diagnostics product portfolio.

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

TABLE OF CONTENTS

1 INTRODUCTION (Page No. - 32)
    1.1 OBJECTIVES OF THE STUDY
    1.2 MARKET DEFINITION
    1.3 MARKET SCOPE
           1.3.1 MARKETS COVERED
           1.3.2 YEARS CONSIDERED FOR THE STUDY
    1.4 CURRENCY USED FOR THE STUDY
    1.5 MAJOR MARKET STAKEHOLDERS
    1.6 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY (Page No. - 36)
    2.1 RESEARCH DATA
           FIGURE 1 RESEARCH DESIGN
           2.1.1 SECONDARY DATA
                    2.1.1.1 Secondary sources
           2.1.2 PRIMARY DATA
                    FIGURE 2 BREAKDOWN OF PRIMARIES: POINT-OF-CARE DIAGNOSTICS MARKET
    2.2 MARKET ESTIMATION METHODOLOGY
           FIGURE 3 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING
           2.2.1 REVENUE MAPPING-BASED MARKET ESTIMATION
           2.2.2 END USER-BASED MARKET ESTIMATION
                    FIGURE 4 MARKET SIZE ESTIMATION: POINT-OF-CARE DIAGNOSTICS MARKET
           2.2.3 PRIMARY RESEARCH VALIDATION
    2.3 DATA TRIANGULATION
           FIGURE 5 DATA TRIANGULATION METHODOLOGY
    2.4 RESEARCH ASSUMPTIONS
    2.5 RESEARCH LIMITATIONS

3 EXECUTIVE SUMMARY (Page No. - 44)
    FIGURE 6 POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2020 VS. 2025 (USD MILLION)
    FIGURE 7 POINT-OF-CARE DIAGNOSTICS MARKET, BY PLATFORM, 2020 VS. 2025 (USD MILLION)
    FIGURE 8 POINT-OF-CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2020 VS. 2025 (USD MILLION)
    FIGURE 9 POINT-OF-CARE DIAGNOSTICS MARKET, BY END USER, 2020 VS. 2025 (USD MILLION)
    FIGURE 10 GEOGRAPHICAL SNAPSHOT OF THE POINT-OF-CARE DIAGNOSTICS MARKET

4 PREMIUM INSIGHTS (Page No. - 48)
    4.1 POINT-OF-CARE DIAGNOSTICS MARKET OVERVIEW
                    FIGURE 11 INCREASINGLY SUPPORTIVE GOVERNMENT POLICIES AND RISING PREVALENCE OF TARGET DISEASES ARE DRIVING THE MARKET GROWTH
    4.2 POINT-OF-CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2020
           FIGURE 12 OTC TESTING PRODUCTS DOMINATE THE POINT-OF-CARE DIAGNOSTICS MARKET IN 2020
    4.3 ASIA PACIFIC: POINT-OF-CARE DIAGNOSTICS MARKET
           FIGURE 13 HOME CARE SETTINGS WERE THE LARGEST END-USER SEGMENT IN THE APAC POC DIAGNOSTICS MARKET IN 2020
    4.4 POINT-OF-CARE DIAGNOSTICS MARKET, BY REGION
           FIGURE 14 APAC TO REGISTER THE HIGHEST GROWTH DURING THE FORECAST PERIOD (2020–2025)

5 MARKET OVERVIEW (Page No. - 52)
    5.1 INTRODUCTION
    5.2 MARKET DYNAMICS
           FIGURE 15 POINT-OF-CARE DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
           5.2.1 DRIVERS
                    5.2.1.1 High prevalence of infectious diseases
                    5.2.1.2 Increasing incidence of target conditions
                    5.2.1.3 Supportive government policies
                    5.2.1.4 Dearth of skilled laboratory technicians
                    5.2.1.5 Rising number of CLIA-waived POC tests
                               TABLE 1 RECENT WAIVERS FOR MARKET PRODUCTS
           5.2.2 RESTRAINTS
                    5.2.2.1 Pricing pressure owing to reimbursement cuts and budget constraints
                    5.2.2.2 Stringent regulatory policies
           5.2.3 OPPORTUNITIES
                    5.2.3.1 Emerging markets
                    5.2.3.2 Healthcare decentralization
                    5.2.3.3 Increasing provider awareness about novel technologies
                    5.2.3.4 POC tests with multiplexing capabilities
                    5.2.3.5 Growing investments and funding for product development
           5.2.4 CHALLENGES
                    5.2.4.1 Lack of alignment with definitive central lab methods
                    5.2.4.2 Inadequate adoption of POC devices in professional settings
                    5.2.4.3 Reluctance to change existing diagnostic practices
                    5.2.4.4 Premium pricing of novel platforms
    5.3 TECHNOLOGY ANALYSIS: EMERGING POINT-OF-CARE APPLICATIONS
           5.3.1 SEPSIS BIOMARKERS
           5.3.2 STROKE/CARDIAC MARKERS
           5.3.3 THYROID TESTING
           5.3.4 DNA TESTING
           5.3.5 ENDOCRINE TESTING
           5.3.6 RESPIRATORY DIAGNOSTICS
    5.4 GLOBAL REGULATORY LANDSCAPE
    5.5 INDUSTRY TRENDS RELATED TO COVID-19
    5.6 VALUE CHAIN ANALYSIS
           FIGURE 16 VALUE CHAIN ANALYSIS—MAXIMUM VALUE ADDED DURING THE REGULATION AND DISTRIBUTION STAGES
    5.7 PRICING TREND ANALYSIS
           TABLE 2 AVERAGE PRICE OF GLUCOSE MONITORING AND CARDIOMETABOLIC MONITORING PRODUCTS, BY COUNTRY, 2019 (USD)
           TABLE 3 AVERAGE PRICE OF INFECTIOUS DISEASE TESTING PRODUCTS, BY COUNTRY, 2019 (USD)
           TABLE 4 AVERAGE PRICE OF OTHER POINT-OF-CARE TESTING PRODUCTS, BY COUNTRY, 2019 (USD)
    5.8 ECOSYSTEM COVERAGE: PARENT MARKET (IN VITRO DIAGNOSTICS)
    5.9 USE CASES: POINT-OF-CARE DIAGNOSTICS MARKET
           5.9.1 REVENUE OPPORTUNITIES: IVD ASSAY DEVELOPMENT SERVICES
           5.9.2 REVENUE OPPORTUNITIES: IVD CONTRACT RESEARCH SERVICES

6 POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT (Page No. - 70)
    6.1 INTRODUCTION
           TABLE 5 POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
    6.2 GLUCOSE MONITORING PRODUCTS
           TABLE 6 POINT-OF-CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 7 POINT-OF-CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY PLATFORM, 2018–2025 (USD MILLION)
           TABLE 8 POINT-OF-CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY MODE OF PURCHASE, 2018–2025 (USD MILLION)
           TABLE 9 POINT-OF-CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY END USER, 2018–2025 (USD MILLION)
           TABLE 10 POINT-OF-CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY REGION, 2018–2025 (USD MILLION)
           6.2.1 STRIPS
                    6.2.1.1 Strips make blood glucose testing easy and hassle-free
                               TABLE 11 GLUCOSE MONITORING STRIPS MARKET, BY REGION, 2018–2025 (USD MILLION)
           6.2.2 METERS
                    6.2.2.1 Blood glucose meters are extremely helpful in the monitoring of blood glucose levels and adjusting therapeutic regimens
                               TABLE 12 GLUCOSE MONITORING METERS MARKET, BY REGION, 2018–2025 (USD MILLION)
           6.2.3 LANCETS & LANCING DEVICES
                    6.2.3.1 Lancets & lancing devices segment to grow at the lowest CAGR in the glucose monitoring products market
                               TABLE 13 GLUCOSE MONITORING LANCETS & LANCING DEVICES MARKET, BY REGION, 2018–2025 (USD MILLION)
    6.3 CARDIOMETABOLIC MONITORING PRODUCTS
           TABLE 14 POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 15 POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY PLATFORM, 2018–2025 (USD MILLION)
           TABLE 16 POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY MODE OF PURCHASE, 2018–2025 (USD MILLION)
           TABLE 17 POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY END USER, 2018–2025 (USD MILLION)
           TABLE 18 POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY REGION, 2018–2025 (USD MILLION)
           6.3.1 CARDIAC MARKER TESTING PRODUCTS
                    6.3.1.1 Rising government initiatives for CVD research will contribute to market growth
                               TABLE 19 POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIAC MARKER TESTING PRODUCTS, BY MODE OF PURCHASE, 2018–2025 (USD MILLION)
                               TABLE 20 POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIAC MARKER TESTING PRODUCTS, BY END USER, 2018–2025 (USD MILLION)
                               TABLE 21 POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIAC MARKER TESTING PRODUCTS, BY REGION, 2018–2025 (USD MILLION)
           6.3.2 BLOOD GAS/ELECTROLYTE TESTING PRODUCTS
                    6.3.2.1 Technological advancements in blood gas/electrolyte products will drive the growth of this market segment
                               TABLE 22 POINT-OF-CARE DIAGNOSTICS MARKET FOR BLOOD GAS/ELECTROLYTE TESTING PRODUCTS, BY MODE OF PURCHASE, 2018–2025 (USD MILLION)
                               TABLE 23 POINT-OF-CARE DIAGNOSTICS MARKET FOR BLOOD GAS/ELECTROLYTE TESTING PRODUCTS, BY END USER, 2018–2025 (USD MILLION)
                               TABLE 24 POINT-OF-CARE DIAGNOSTICS MARKET FOR BLOOD GAS/ELECTROLYTE TESTING PRODUCTS, BY REGION, 2018–2025 (USD MILLION)
           6.3.3 HBA1C TESTING PRODUCTS
                    6.3.3.1 Government initiatives are promoting the regular use of HbA1c testing
                               TABLE 25 POINT-OF-CARE DIAGNOSTICS MARKET FOR HBA1C TESTING PRODUCTS, BY MODE OF PURCHASE, 2018–2025 (USD MILLION)
                               TABLE 26 POINT-OF-CARE DIAGNOSTICS MARKET FOR HBA1C TESTING PRODUCTS, BY END USER, 2018–2025 (USD MILLION)
                               TABLE 27 POINT-OF-CARE DIAGNOSTICS MARKET FOR HBA1C TESTING PRODUCTS, BY REGION, 2018–2025 (USD MILLION)
    6.4 INFECTIOUS DISEASE TESTING PRODUCTS
           TABLE 28 POINT-OF-CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 29 POINT-OF-CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY PLATFORM, 2018–2025 (USD MILLION)
           TABLE 30 POINT-OF-CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY MODE OF PURCHASE, 2018–2025 (USD MILLION)
           TABLE 31 POINT-OF-CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY END USER, 2018–2025 (USD MILLION)
           TABLE 32 POINT-OF-CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY REGION, 2018–2025 (USD MILLION)
           6.4.1 HIV TESTING PRODUCTS
                    6.4.1.1 Rising prevalence of HIV to drive market growth
                               TABLE 33 POINT-OF-CARE DIAGNOSTICS MARKET FOR HIV TESTING PRODUCTS, BY MODE OF PURCHASE, 2018–2025 (USD MILLION)
                               TABLE 34 POINT-OF-CARE DIAGNOSTICS MARKET FOR HIV TESTING PRODUCTS, BY END USER, 2018–2025 (USD MILLION)
                               TABLE 35 POINT-OF-CARE DIAGNOSTICS MARKET FOR HIV TESTING PRODUCTS, BY REGION, 2018–2025 (USD MILLION)
           6.4.2 RESPIRATORY INFECTION TESTING PRODUCTS
                    6.4.2.1 POCT products for the diagnosis of respiratory infections offer lower sensitivity as compared to other tests
                               TABLE 36 POINT-OF-CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY MODE OF PURCHASE, 2018–2025 (USD MILLION)
                               TABLE 37 POINT-OF-CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY END USER, 2018–2025 (USD MILLION)
                               TABLE 38 POINT-OF-CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY REGION, 2018–2025 (USD MILLION)
           6.4.3 HEPATITIS C TESTING PRODUCTS
                    6.4.3.1 Central and East Asia are among the highly affected regions with Hepatitis C
                               TABLE 39 POINT-OF-CARE DIAGNOSTICS MARKET FOR HEPATITIS C TESTING PRODUCTS, BY MODE OF PURCHASE, 2018–2025 (USD MILLION)
                               TABLE 40 POINT-OF-CARE DIAGNOSTICS MARKET FOR HEPATITIS C TESTING PRODUCTS, BY END USER, 2018–2025 (USD MILLION)
                               TABLE 41 POINT-OF-CARE DIAGNOSTICS MARKET FOR HEPATITIS C TESTING PRODUCTS, BY REGION, 2018–2025 (USD MILLION)
           6.4.4 HEALTHCARE-ASSOCIATED INFECTION TESTING PRODUCTS
                    6.4.4.1 Rising prevalence of HAIs is the key factor driving market growth
                               TABLE 42 POINT-OF-CARE DIAGNOSTICS MARKET FOR HEALTHCARE-ASSOCIATED INFECTION TESTING PRODUCTS, BY MODE OF PURCHASE, 2018–2025 (USD MILLION)
                               TABLE 43 POINT-OF-CARE DIAGNOSTICS MARKET FOR HEALTHCARE-ASSOCIATED INFECTION TESTING PRODUCTS, BY END USER, 2018–2025 (USD MILLION)
                               TABLE 44 POINT-OF-CARE DIAGNOSTICS MARKET FOR HEALTHCARE-ASSOCIATED INFECTION TESTING PRODUCTS, BY REGION, 2018–2025 (USD MILLION)
           6.4.5 INFLUENZA TESTING PRODUCTS
                    6.4.5.1 Rising influenza prevalence has driven the demand for influenza testing products
                               TABLE 45 POINT-OF-CARE DIAGNOSTICS MARKET FOR INFLUENZA TESTING PRODUCTS, BY MODE OF PURCHASE, 2018–2025 (USD MILLION)
                               TABLE 46 POINT-OF-CARE DIAGNOSTICS MARKET FOR INFLUENZA TESTING PRODUCTS, BY END USER, 2018–2025 (USD MILLION)
                               TABLE 47 POINT-OF-CARE DIAGNOSTICS MARKET FOR INFLUENZA TESTING PRODUCTS, BY REGION, 2018–2025 (USD MILLION)
           6.4.6 TROPICAL DISEASE TESTING PRODUCTS
                    6.4.6.1 Increasing government funding for the use of POC in tropical disease testing will support market growth
                               TABLE 48 POINT-OF-CARE DIAGNOSTICS MARKET FOR TROPICAL DISEASE TESTING PRODUCTS, BY MODE OF PURCHASE, 2018–2025 (USD MILLION)
                               TABLE 49 POINT-OF-CARE DIAGNOSTICS MARKET FOR TROPICAL DISEASE TESTING PRODUCTS, BY END USER, 2018–2025 (USD MILLION)
                               TABLE 50 POINT-OF-CARE DIAGNOSTICS MARKET FOR TROPICAL DISEASE TESTING PRODUCTS, BY REGION, 2018–2025 (USD MILLION)
           6.4.7 SEXUALLY TRANSMITTED DISEASE TESTING PRODUCTS
                    6.4.7.1 Privacy and confidentiality issues are the key factors leading to the adoption of POC STD testing products
                               TABLE 51 POINT-OF-CARE DIAGNOSTICS MARKET FOR STD TESTING PRODUCTS, BY MODE OF PURCHASE, 2018–2025 (USD MILLION)
                               TABLE 52 POINT-OF-CARE DIAGNOSTICS MARKET FOR STD TESTING PRODUCTS, BY END USER, 2018–2025 (USD MILLION)
                               TABLE 53 POINT-OF-CARE DIAGNOSTICS MARKET FOR STD TESTING PRODUCTS, BY REGION, 2018–2025 (USD MILLION)
           6.4.8 OTHER INFECTIOUS DISEASE TESTING PRODUCTS
                    TABLE 54 POINT-OF-CARE DIAGNOSTICS MARKET FOR OTHER INFECTIOUS DISEASE TESTING PRODUCTS, BY MODE OF PURCHASE, 2018–2025 (USD MILLION)
                    TABLE 55 POINT-OF-CARE DIAGNOSTICS MARKET FOR OTHER INFECTIOUS DISEASE TESTING PRODUCTS, BY END USER, 2018–2025 (USD MILLION)
                    TABLE 56 POINT-OF-CARE DIAGNOSTICS MARKET FOR OTHER INFECTIOUS DISEASE TESTING PRODUCTS, BY REGION, 2018–2025 (USD MILLION)
    6.5 COAGULATION MONITORING PRODUCTS
           TABLE 57 POINT-OF-CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 58 POINT-OF-CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY PLATFORM, 2018–2025 (USD MILLION)
           TABLE 59 POINT-OF-CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY MODE OF PURCHASE, 2018–2025 (USD MILLION)
           TABLE 60 POINT-OF-CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY END USER, 2018–2025 (USD MILLION)
           TABLE 61 POINT-OF-CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY REGION, 2018–2025 (USD MILLION)
           6.5.1 PT/INR TESTING PRODUCTS
                    6.5.1.1 PT/INR is one of the most commonly used coagulation monitoring methods
                               TABLE 62 POINT-OF-CARE DIAGNOSTICS MARKET FOR PT/INR TESTING PRODUCTS, BY MODE OF PURCHASE, 2018–2025 (USD MILLION)
                               TABLE 63 POINT-OF-CARE DIAGNOSTICS MARKET FOR PT/INR TESTING PRODUCTS, BY END USER, 2018–2025 (USD MILLION)
                               TABLE 64 POINT-OF-CARE DIAGNOSTICS MARKET FOR PT/INR TESTING PRODUCTS, BY REGION, 2018–2025 (USD MILLION)
           6.5.2 ACT/APTT TESTING PRODUCTS
                    6.5.2.1 Rising number of patients undergoing angioplasty and dialysis globally to support market growth
                               TABLE 65 POINT-OF-CARE DIAGNOSTICS MARKET FOR ACT/APTT TESTING PRODUCTS, BY MODE OF PURCHASE, 2018–2025 (USD MILLION)
                               TABLE 66 POINT-OF-CARE DIAGNOSTICS MARKET FOR ACT/APTT TESTING PRODUCTS, BY END USER, 2018–2025 (USD MILLION)
                               TABLE 67 POINT-OF-CARE DIAGNOSTICS MARKET FOR ACT/APTT TESTING PRODUCTS, BY REGION, 2018–2025 (USD MILLION)
    6.6 PREGNANCY & FERTILITY TESTING PRODUCTS
           TABLE 68 POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 69 POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY PLATFORM, 2018–2025 (USD MILLION)
           TABLE 70 POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY MODE OF PURCHASE, 2018–2025 (USD MILLION)
           TABLE 71 POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY END USER, 2018–2025 (USD MILLION)
           TABLE 72 POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY REGION, 2018–2025 (USD MILLION)
           6.6.1 PREGNANCY TESTING PRODUCTS
                    6.6.1.1 Rising inclination toward home testing to support market growth
                               TABLE 73 POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY TESTING PRODUCTS, BY MODE OF PURCHASE, 2018–2025 (USD MILLION)
                               TABLE 74 POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY TESTING PRODUCTS, BY END USER, 2018–2025 (USD MILLION)
                               TABLE 75 POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY TESTING PRODUCTS, BY REGION, 2018–2025 (USD MILLION)
           6.6.2 FERTILITY TESTING PRODUCTS
                    6.6.2.1 Increasing awareness of fertility testing to drive market growth
                               TABLE 76 POINT-OF-CARE DIAGNOSTICS MARKET FOR FERTILITY TESTING PRODUCTS, BY MODE OF PURCHASE, 2018–2025 (USD MILLION)
                               TABLE 77 POINT-OF-CARE DIAGNOSTICS MARKET FOR FERTILITY TESTING PRODUCTS, BY END USER, 2018–2025 (USD MILLION)
                               TABLE 78 POINT-OF-CARE DIAGNOSTICS MARKET FOR FERTILITY TESTING PRODUCTS, BY REGION, 2018–2025 (USD MILLION)
    6.7 TUMOR/CANCER MARKER TESTING PRODUCTS
           6.7.1 INCREASING INVESTMENTS FOR RESEARCH RELATED TO POC CANCER TESTING ARE DRIVING MARKET GROWTH
                    TABLE 79 POINT-OF-CARE DIAGNOSTICS MARKET FOR TUMOR/CANCER MARKER TESTING PRODUCTS, BY PLATFORM, 2018–2025 (USD MILLION)
                    TABLE 80 POINT-OF-CARE DIAGNOSTICS MARKET FOR TUMOR/CANCER MARKER TESTING PRODUCTS, BY MODE OF PURCHASE, 2018–2025 (USD MILLION)
                    TABLE 81 POINT-OF-CARE DIAGNOSTICS MARKET FOR TUMOR/CANCER MARKER TESTING PRODUCTS, BY END USER, 2018–2025 (USD MILLION)
                    TABLE 82 POINT-OF-CARE DIAGNOSTICS MARKET FOR TUMOR/CANCER MARKER TESTING PRODUCTS, BY REGION, 2018–2025 (USD MILLION)
    6.8 URINALYSIS TESTING PRODUCTS
           6.8.1 RISING PREVALENCE OF URINARY TRACT INFECTIONS IS DRIVING MARKET GROWTH
                    TABLE 83 POINT-OF-CARE DIAGNOSTICS MARKET FOR URINALYSIS TESTING PRODUCTS, BY PLATFORM, 2018–2025 (USD MILLION)
                    TABLE 84 POINT-OF-CARE DIAGNOSTICS MARKET FOR URINALYSIS TESTING PRODUCTS, BY MODE OF PURCHASE, 2018–2025 (USD MILLION)
                    TABLE 85 POINT-OF-CARE DIAGNOSTICS MARKET FOR URINALYSIS TESTING PRODUCTS, BY END USER, 2018–2025 (USD MILLION)
                    TABLE 86 POINT-OF-CARE DIAGNOSTICS MARKET FOR URINALYSIS TESTING PRODUCTS, BY REGION, 2018–2025 (USD MILLION)
    6.9 CHOLESTEROL TESTING PRODUCTS
           6.9.1 RISING OBESITY LEVELS & CARDIOVASCULAR DISORDER INCIDENCE ARE THE KEY FACTORS SUPPORTING MARKET GROWTH
                    TABLE 87 POINT-OF-CARE DIAGNOSTICS MARKET FOR CHOLESTEROL TESTING PRODUCTS, BY PLATFORM, 2018–2025 (USD MILLION)
                    TABLE 88 POINT-OF-CARE DIAGNOSTICS MARKET FOR CHOLESTEROL TESTING PRODUCTS, BY MODE OF PURCHASE, 2018–2025 (USD MILLION)
                    TABLE 89 POINT-OF-CARE DIAGNOSTICS MARKET FOR CHOLESTEROL TESTING PRODUCTS, BY END USER, 2018–2025 (USD MILLION)
                    TABLE 90 POINT-OF-CARE DIAGNOSTICS MARKET FOR CHOLESTEROL TESTING PRODUCTS, BY REGION, 2018–2025 (USD MILLION)
    6.1 HEMATOLOGY TESTING PRODUCTS
           6.10.1 PREFERENCE FOR LABORATORY-BASED TESTS AMONG USERS WILL IMPEDE MARKET GROWTH
                    TABLE 91 POINT-OF-CARE DIAGNOSTICS MARKET FOR HEMATOLOGY TESTING PRODUCTS, BY PLATFORM, 2018–2025 (USD MILLION)
                    TABLE 92 POINT-OF-CARE DIAGNOSTICS MARKET FOR HEMATOLOGY TESTING PRODUCTS, BY MODE OF PURCHASE, 2018–2025 (USD MILLION)
                    TABLE 93 POINT-OF-CARE DIAGNOSTICS MARKET FOR HEMATOLOGY TESTING PRODUCTS, BY END USER, 2018–2025 (USD MILLION)
                    TABLE 94 POINT-OF-CARE DIAGNOSTICS MARKET FOR HEMATOLOGY TESTING PRODUCTS, BY REGION, 2018–2025 (USD MILLION)
    6.11 DRUGS-OF-ABUSE TESTING PRODUCTS
           6.11.1 RISING CONSUMPTION OF ILLICIT DRUGS HAS BOOSTED DEMAND FOR TESTING
                    TABLE 95 POINT-OF-CARE DIAGNOSTICS MARKET FOR DRUGS-OF-ABUSE TESTING PRODUCTS, BY PLATFORM, 2018–2025 (USD MILLION)
                    TABLE 96 POINT-OF-CARE DIAGNOSTICS MARKET FOR DRUGS-OF-ABUSE TESTING PRODUCTS, BY MODE OF PURCHASE, 2018–2025 (USD MILLION)
                    TABLE 97 POINT-OF-CARE DIAGNOSTICS MARKET FOR DRUGS-OF-ABUSE TESTING PRODUCTS, BY END USER, 2018–2025 (USD MILLION)
                    TABLE 98 POINT-OF-CARE DIAGNOSTICS MARKET FOR DRUGS-OF-ABUSE TESTING PRODUCTS, BY REGION, 2018–2025 (USD MILLION)
    6.12 FECAL OCCULT TESTING PRODUCTS
           6.12.1 LACK OF PROPER TRAINING IN THE USE OF FECAL OCCULT TESTING TO HAMPER MARKET ADOPTION
                    TABLE 99 POINT-OF-CARE DIAGNOSTICS MARKET FOR FECAL OCCULT TESTING PRODUCTS, BY PLATFORM, 2018–2025 (USD MILLION)
                    TABLE 100 POINT-OF-CARE DIAGNOSTICS MARKET FOR FECAL OCCULT TESTING PRODUCTS, BY MODE OF PURCHASE, 2018–2025 (USD MILLION)
                    TABLE 101 POINT-OF-CARE DIAGNOSTICS MARKET FOR FECAL OCCULT TESTING PRODUCTS, BY END USER, 2018–2025 (USD MILLION)
                    TABLE 102 POINT-OF-CARE DIAGNOSTICS MARKET FOR FECAL OCCULT TESTING PRODUCTS, BY REGION, 2018–2025 (USD MILLION)
    6.13 OTHER POC PRODUCTS
                    TABLE 103 POINT-OF-CARE DIAGNOSTICS MARKET FOR OTHER POC PRODUCTS, BY PLATFORM, 2018–2025 (USD MILLION)
                    TABLE 104 POINT-OF-CARE DIAGNOSTICS MARKET FOR OTHER PRODUCTS, BY MODE OF PURCHASE, 2018–2025 (USD MILLION)
                    TABLE 105 POINT-OF-CARE DIAGNOSTICS MARKET FOR OTHER POC PRODUCTS, BY END USER, 2018–2025 (USD MILLION)
                    TABLE 106 POINT-OF-CARE DIAGNOSTICS MARKET FOR OTHER POC PRODUCTS, BY REGION, 2018–2025 (USD MILLION)

7 POINT-OF-CARE DIAGNOSTICS MARKET, BY PLATFORM (Page No. - 118)
    7.1 INTRODUCTION
           TABLE 107 POINT-OF-CARE DIAGNOSTICS MARKET, BY PLATFORM, 2018–2025 (USD MILLION)
    7.2 LATERAL FLOW ASSAYS
           7.2.1 TECHNOLOGICAL ADVANCEMENTS AND INCREASING ADOPTION OF LFA ARE SUPPORTING MARKET GROWTH
                    TABLE 108 POINT-OF-CARE DIAGNOSTICS MARKET FOR LATERAL FLOW ASSAYS, BY REGION, 2018–2025 (USD MILLION)
    7.3 IMMUNOASSAYS
           7.3.1 RISING INCIDENCE OF CANCER AND GROWING AWARENESS ABOUT IMMUNOASSAY PLATFORMS TO SUPPORT MARKET GROWTH
                    TABLE 109 POINT-OF-CARE DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY REGION, 2018–2025 (USD MILLION)
    7.4 MICROFLUIDICS
           7.4.1 MICROFLUIDICS IS AN EMERGING PLATFORM IN THE POC DIAGNOSTICS MARKET
                    TABLE 110 POINT-OF-CARE DIAGNOSTICS MARKET FOR MICROFLUIDICS, BY REGION, 2018–2025 (USD MILLION)
    7.5 DIPSTICKS
           7.5.1 DIPSTICKS HELP IN THE ROUTINE ANALYSIS OF SEVERAL MEDICAL CONDITIONS
                    TABLE 111 POINT-OF-CARE DIAGNOSTICS MARKET FOR DIPSTICKS, BY REGION, 2018–2025 (USD MILLION)
    7.6 MOLECULAR DIAGNOSTICS
           7.6.1 INCREASING INITIATIVES BY MARKET PLAYERS FOR DEVELOPING POC MOLECULAR DIAGNOSTIC PRODUCTS TO DRIVE MARKET GROWTH
                    TABLE 112 POINT-OF-CARE DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY REGION, 2018–2025 (USD MILLION)

8 POINT-OF-CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE (Page No. - 125)
    8.1 INTRODUCTION
           TABLE 113 POINT-OF-CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2018–2025 (USD MILLION)
    8.2 OTC TESTING PRODUCTS
           8.2.1 RISING FOCUS ON HOME CARE IS EXPECTED TO BOOST THE DEMAND FOR OTC TESTING IN THE COMING YEARS
                    TABLE 114 OTC POINT-OF-CARE TESTING PRODUCTS MARKET, BY REGION, 2018–2025 (USD MILLION)
    8.3 PRESCRIPTION-BASED TESTING PRODUCTS
           8.3.1 GROWING PREVALENCE OF LIFESTYLE DISEASES AND FAVORABLE REIMBURSEMENT HAVE DRIVEN MARKET GROWTH
                    TABLE 115 PRESCRIPTION-BASED POINT-OF-CARE TESTING PRODUCTS MARKET, BY REGION, 2018–2025 (USD MILLION)

9 POINT-OF-CARE DIAGNOSTICS MARKET, BY END USER (Page No. - 129)
    9.1 INTRODUCTION
           TABLE 116 POINT-OF-CARE DIAGNOSTICS MARKET, BY END USER, 2018–2025 (USD MILLION)
    9.2 OUTPATIENT & AMBULATORY CARE FACILITIES
           9.2.1 RAPID RESULT GENERATION AND AVAILABILITY OF IMMEDIATE PATIENT CARE ARE THE MAJOR FACTORS DRIVING MARKET GROWTH
                    TABLE 117 POINT-OF-CARE DIAGNOSTICS MARKET FOR OUTPATIENT & AMBULATORY CARE FACILITIES, BY REGION, 2018–2025 (USD MILLION)
    9.3 HOSPITALS & CRITICAL CARE CENTERS
           9.3.1 HOSPITALS ARE AMONG THE LARGEST END USERS OF POC DIAGNOSTICS
                    TABLE 118 POINT-OF-CARE DIAGNOSTICS MARKET FOR HOSPITALS & CRITICAL CARE CENTERS, BY REGION, 2018–2025 (USD MILLION)
    9.4 HOME CARE SETTINGS
           9.4.1 INCREASING INCLINATION TOWARD HOME HEALTHCARE IS DRIVING THE GROWTH OF THIS END-USER SEGMENT
                    TABLE 119 POINT-OF-CARE DIAGNOSTICS MARKET FOR HOME CARE SETTINGS, BY REGION, 2018–2025 (USD MILLION)
    9.5 OTHER END USERS
           TABLE 120 POINT-OF-CARE DIAGNOSTICS MARKET FOR OTHER END USERS, BY REGION, 2018–2025 (USD MILLION)

10 POINT-OF-CARE DIAGNOSTICS MARKET, BY REGION (Page No. - 134)
     10.1 INTRODUCTION
               TABLE 121 POINT-OF-CARE DIAGNOSTICS MARKET, BY REGION, 2018–2025 (USD MILLION)
     10.2 NORTH AMERICA
               FIGURE 17 NORTH AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET SNAPSHOT
               TABLE 122 NORTH AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
               TABLE 123 NORTH AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
               TABLE 124 NORTH AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2018–2025 (USD MILLION)
               TABLE 125 NORTH AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2018–2025 (USD MILLION)
               TABLE 126 NORTH AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2018–2025 (USD MILLION)
               TABLE 127 NORTH AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2018–2025 (USD MILLION)
               TABLE 128 NORTH AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2018–2025 (USD MILLION)
               TABLE 129 NORTH AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET, BY PLATFORM, 2018–2025 (USD MILLION)
               TABLE 130 NORTH AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2018–2025 (USD MILLION)
               TABLE 131 NORTH AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET, BY END USER, 2018–2025 (USD MILLION)
             10.2.1 US
                       10.2.1.1 The US dominates the North American market for POC diagnostics
                                   TABLE 132 US: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
             10.2.2 CANADA
                       10.2.2.1 Rising government initiatives to support the growth of the POC diagnostics market in Canada
                                   TABLE 133 CANADA: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
     10.3 EUROPE
               TABLE 134 EUROPE: POINT-OF-CARE DIAGNOSTICS MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
               TABLE 135 EUROPE: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
               TABLE 136 EUROPE: POINT-OF-CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2018–2025 (USD MILLION)
               TABLE 137 EUROPE: POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2018–2025 (USD MILLION)
               TABLE 138 EUROPE: POINT-OF-CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2018–2025 (USD MILLION)
               TABLE 139 EUROPE: POINT-OF-CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2018–2025 (USD MILLION)
               TABLE 140 EUROPE: POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2018–2025 (USD MILLION)
               TABLE 141 EUROPE: POINT-OF-CARE DIAGNOSTICS MARKET, BY PLATFORM, 2018–2025 (USD MILLION)
               TABLE 142 EUROPE: POINT-OF-CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2018–2025 (USD MILLION)
               TABLE 143 EUROPE: POINT-OF-CARE DIAGNOSTICS MARKET, BY END USER, 2018–2025 (USD MILLION)
             10.3.1 GERMANY
                       10.3.1.1 Germany accounts for the largest share of the European market
                                   TABLE 144 GERMANY: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
             10.3.2 FRANCE
                       10.3.2.1 Growing public-private collaborations for product development to drive market growth
                                   TABLE 145 FRANCE: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
             10.3.3 UK
                       10.3.3.1 Growing awareness of the benefits offered by POC diagnostics to support market growth in the UK
                                   TABLE 146 UK: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
             10.3.4 ITALY
                       10.3.4.1 Rising prevalence of chronic diseases in Italy to drive the demand for point-of-care diagnostics
                                   TABLE 147 ITALY: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
             10.3.5 SPAIN
                       10.3.5.1 Increasing funding for research in Spain to boost market growth
                                   TABLE 148 SPAIN: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
             10.3.6 REST OF EUROPE
                       TABLE 149 ROE: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
     10.4 ASIA PACIFIC
               FIGURE 18 APAC: POINT-OF-CARE DIAGNOSTICS MARKET SNAPSHOT
               TABLE 150 APAC: POINT-OF-CARE DIAGNOSTICS MARKET, BY COUNTRY,  2018–2025 (USD MILLION)
               TABLE 151 APAC: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT,  2018–2025 (USD MILLION)
               TABLE 152 APAC: POINT-OF-CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2018–2025 (USD MILLION)
               TABLE 153 APAC: POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2018–2025 (USD MILLION)
               TABLE 154 APAC: POINT-OF-CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2018–2025 (USD MILLION)
               TABLE 155 APAC: POINT-OF-CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2018–2025 (USD MILLION)
               TABLE 156 APAC: POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2018–2025 (USD MILLION)
               TABLE 157 APAC: POINT-OF-CARE DIAGNOSTICS MARKET, BY PLATFORM, 2018–2025 (USD MILLION)
               TABLE 158 APAC: POINT-OF-CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2018–2025 (USD MILLION)
               TABLE 159 APAC: POINT-OF-CARE DIAGNOSTICS MARKET, BY END USER, 2018–2025 (USD MILLION)
             10.4.1 JAPAN
                       10.4.1.1 Japan to dominate the APAC POC diagnostics market during the forecast period
                                   TABLE 160 JAPAN: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
             10.4.2 CHINA
                       10.4.2.1 Rising investments by market players and the Chinese government to drive market growth
                                   TABLE 161 CHINA: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
             10.4.3 INDIA
                       10.4.3.1 High burden of chronic diseases to support market growth
                                   TABLE 162 INDIA: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
             10.4.4 AUSTRALIA
                       10.4.4.1 High burden of chronic diseases to support market growth
                                   TABLE 163 AUSTRALIA: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
             10.4.5 SOUTH KOREA
                       10.4.5.1 Increased funding and product development to propel market growth
                                   TABLE 164 SOUTH KOREA: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
             10.4.6 REST OF ASIA PACIFIC
                       TABLE 165 ROAPAC: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
     10.5 LATIN AMERICA
               TABLE 166 LATAM: POINT-OF-CARE DIAGNOSTICS MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
               TABLE 167 LATAM: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
               TABLE 168 LATAM: POINT-OF-CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2018–2025 (USD MILLION)
               TABLE 169 LATAM: POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2018–2025 (USD MILLION)
               TABLE 170 LATAM: POINT-OF-CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2018–2025 (USD MILLION)
               TABLE 171 LATAM: POINT-OF-CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2018–2025 (USD MILLION)
               TABLE 172 LATAM: POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2018–2025 (USD MILLION)
               TABLE 173 LATAM: POINT-OF-CARE DIAGNOSTICS MARKET, BY PLATFORM, 2018–2025 (USD MILLION)
               TABLE 174 LATAM: POINT-OF-CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2018–2025 (USD MILLION)
               TABLE 175 LATAM: POINT-OF-CARE DIAGNOSTICS MARKET, BY END USER, 2018–2025 (USD MILLION)
             10.5.1 BRAZIL
                       10.5.1.1 Rising prevalence of diabetes to support market growth in Brazil
                                   TABLE 176 BRAZIL: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
             10.5.2 MEXICO
                       10.5.2.1 Rising prevalence of diabetes and cancer to support market growth in Mexico
                                   TABLE 177 MEXICO: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
             10.5.3 REST OF LATIN AMERICA
                       TABLE 178 ROLATAM: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
     10.6 MIDDLE EAST & AFRICA
             10.6.1 RISING PREVALENCE OF CANCER TO SUPPORT MARKET GROWTH IN THE MEA
                       TABLE 179 MIDDLE EAST & AFRICA: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
                       TABLE 180 MIDDLE EAST & AFRICA: POINT-OF-CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2018–2025 (USD MILLION)
                       TABLE 181 MIDDLE EAST & AFRICA: POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2018–2025 (USD MILLION)
                       TABLE 182 MIDDLE EAST & AFRICA: POINT-OF-CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2018–2025 (USD MILLION)
                       TABLE 183 MIDDLE EAST & AFRICA: POINT-OF-CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2018–2025 (USD MILLION)
                       TABLE 184 MIDDLE EAST & AFRICA: POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2018–2025 (USD MILLION)
                       TABLE 185 MIDDLE EAST & AFRICA: POINT-OF-CARE DIAGNOSTICS MARKET, BY PLATFORM, 2018–2025 (USD MILLION)
                       TABLE 186 MIDDLE EAST & AFRICA: POINT-OF-CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2018–2025 (USD MILLION)
                       TABLE 187 MIDDLE EAST & AFRICA: POINT-OF-CARE DIAGNOSTICS MARKET, BY END USER, 2018–2025 (USD MILLION)

11 COMPETITIVE LANDSCAPE (Page No. - 178)
     11.1 OVERVIEW
               FIGURE 19 KEY DEVELOPMENTS IN THE POINT-OF-CARE DIAGNOSTICS MARKET (2017–2020)
     11.2 MARKET SHARE ANALYSIS (2019)
               FIGURE 20 ROCHE DIAGNOSTICS HELD THE LEADING POSITION IN THE MARKET IN 2019
     11.3 COMPETITIVE SCENARIO (2016–2020)
               FIGURE 21 STRATEGIC OVERVIEW: MAJOR PLAYERS (2016–2020)
             11.3.1 KEY PRODUCT LAUNCHES & PRODUCT APPROVALS (2016–2020)
             11.3.2 KEY ACQUISITIONS (2016–2020)
             11.3.3 KEY AGREEMENTS, CONTRACTS, AND PARTNERSHIPS (2016–2020)
     11.4 COMPETITIVE LEADERSHIP MAPPING: MAJOR GLOBAL PLAYERS (AS OF 2019)
             11.4.1 STARS
             11.4.2 EMERGING LEADERS
             11.4.3 PERVASIVE PLAYERS
             11.4.4 PARTICIPANTS
                       FIGURE 22 POINT-OF-CARE DIAGNOSTICS MARKET: COMPETITIVE LEADERSHIP MAPPING, 2019 (MAJOR GLOBAL PLAYERS)
     11.5 COMPETITIVE LEADERSHIP MAPPING: EMERGING COMPANIES/SMES/START-UPS (AS OF 2019)
             11.5.1 PROGRESSIVE COMPANIES
             11.5.2 STARTING BLOCKS
             11.5.3 RESPONSIVE COMPANIES
             11.5.4 DYNAMIC COMPANIES

12 COMPANY PROFILES (Page No. - 187)
(Business Overview, Products Offered, Recent Developments, MnM View)*
     12.1 ROCHE DIAGNOSTICS
               FIGURE 24 ROCHE DIAGNOSTICS: COMPANY SNAPSHOT
     12.2 SIEMENS HEALTHINEERS
               FIGURE 25 SIEMENS HEALTHINEERS: COMPANY SNAPSHOT
     12.3 DANAHER CORPORATION
               FIGURE 26 DANAHER CORPORATION: COMPANY SNAPSHOT
     12.4 BECTON, DICKINSON AND COMPANY
               FIGURE 27 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT
     12.5 ABBOTT LABORATORIES
               FIGURE 28 ABBOTT LABORATORIES: COMPANY SNAPSHOT
     12.6 QUIDEL CORPORATION
               FIGURE 29 QUIDEL CORPORATION: COMPANY SNAPSHOT
     12.7 CHEMBIO DIAGNOSTICS
               FIGURE 30 CHEMBIO DIAGNOSTICS: COMPANY SNAPSHOT
     12.8 JOHNSON & JOHNSON
               FIGURE 31 JOHNSON & JOHNSON: COMPANY SNAPSHOT
     12.9 EKF DIAGNOSTICS
               FIGURE 32 EKF DIAGNOSTICS: COMPANY SNAPSHOT
     12.10 TRINITY BIOTECH
               FIGURE 33 TRINITY BIOTECH: COMPANY SNAPSHOT
     12.11 ACCUBIOTECH
     12.12 INSTRUMENTATION LABORATORY (A WERFEN COMPANY)
     12.13 NOVA BIOMEDICAL
     12.14 PTS DIAGNOSTICS
     12.15 SEKISUI DIAGNOSTICS
     12.16 FLUXERGY

*Business Overview, Products Offered, Recent Developments, MnM View might not be captured in case of unlisted companies.

13 APPENDIX (Page No. - 232)
     13.1 DISCUSSION GUIDE
     13.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
     13.3 AVAILABLE CUSTOMIZATIONS
     13.4 RELATED REPORTS
     13.5 AUTHOR DETAILS

The study involved four major activities to estimate the current size of the point-of-care diagnostics market. Exhaustive secondary research was carried out to collect information on the market and its different subsegments. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Top-down and bottom-up approaches were employed to estimate the complete market size. Thereafter, market breakdown and data triangulation procedures were used to estimate the size of segments and subsegments.

Secondary Research

In the secondary research process, various secondary sources, such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, regulatory bodies, and publications from government sources [such as National Institutes of Health (NIH), US FDA, US Census Bureau, World Health Organization (WHO), ‘Organisation for Economic Co-operation and Development (OECD),were referred to identify and collect information for the point of care diagnostics market study.

Primary Research

The point of care diagnostics market comprises several stakeholders such as manufacturers of point of care diagnostics, Healthcare service providers, diagnostic companies, , Public and private research organizations, Research laboratories and academic institutes, Market research and consulting firms The demand side of this market is characterized by the increasing incidence of infectious diseases and technological advancements, and increased funding and public-private investments. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information. The following is the breakdown of primary respondents:

Point of Care/Rapid Diagnostics Market  Size, and Share

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

Both top-down and bottom-up approaches were used to estimate and validate the total size of the point of care diagnostics market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

  • The key players in the industry and markets have been identified through extensive secondary research
  • The industry’s supply chain and market size, in terms of value, have been determined through primary and secondary research
  • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources

Point of Care/Rapid Diagnostics Market  Size, and Share

Data Triangulation

After arriving at the overall size of the global point-of-care diagnostics market through the above-mentioned methodology, this market was split into several segments and subsegments. The data triangulation and market breakdown procedures were employed, wherever applicable, to complete the overall market engineering process and arrive at the exact market value data for the key segments and subsegments. The extrapolated market data was triangulated by studying various macro indicators and regional trends from both demand- and supply-side participants.

Report Objectives

  • To define, describe, and forecast the global point of care diagnostics market on the basis of product, platform, mode of purchase, end user, and region.
  • To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
  • To strategically analyze micromarkets1 with respect to individual growth trends, future prospects, and contributions to the overall market
  • To analyze the opportunities in the market for key stakeholders and provide details of the competitive landscape for major market leaders
  • To forecast the size of the market segments with respect to five main regions, namely, North America (the US and Canada), Europe (Germany, the UK, France, Italy, Spain, and Rest of Europe), Asia Pacific (Japan, China, India, Australia, South Korea, and Rest of Asia Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), and the Middle East & Africa
  • To profile the key market players and comprehensively analyze their market shares and core competencies2
  • To track and analyze competitive developments such as mergers and acquisitions, new product developments, partnerships, agreements, collaborations, and expansions in the global point of care diagnostics market

Available Customizations

With the given market data, MarketsandMarkets offers customizations as per your company’s specific needs. The following customization options are available for the global point-of-care diagnostics market report

Product Analysis

  • Product Matrix, which gives a detailed comparison of the product portfolios of the top five global players.

Company Information

  • Detailed analysis and profiling of additional market players (up to 5 OEMs)

Geographic Analysis

  • Further breakdown of the Rest of Europe point-of-care diagnostics market into Belgium, Austria,
  • Denmark, Greece, Poland, and Russia, among other countries
  • Further breakdown of the Rest of Asia Pacific point-of-care diagnostics market into New Zealand, Vietnam, Philippines, Singapore, Malaysia, Thailand, and Indonesia, among other countries
  • Further breakdown of the Rest of Latin America point-of-care diagnostics market into Argentina, and Colombia, among other countries.
COVID-19

Get in-depth analysis of the COVID-19 impact on the Point of Care/Rapid Diagnostics Market

Benchmarking the rapid strategy shifts of the Top 100 companies in the Point of Care/Rapid Diagnostics Market

Request For Special Pricing
Report Code
MD 2702
Published ON
Feb, 2021
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Point of Care/Rapid Diagnostics Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
CUSTOMIZED WORKSHOP REQUEST
ADJACENT MARKETS
REQUEST BUNDLE REPORTS
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2021 MarketsandMarkets Research Private Ltd. All rights reserved
...

Digital Virtual Assistant - MarketsandMarkets

Home